

# Attilio Guarini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6847637/publications.pdf>

Version: 2024-02-01

59  
papers

2,061  
citations

394421

19  
h-index

243625

44  
g-index

61  
all docs

61  
docs citations

61  
times ranked

3526  
citing authors

#	ARTICLE	IF	CITATIONS
1	Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2022, 14, 519.	3.7	2
2	Echocardiography Monitoring during Anthracycline Administration in Hodgkin and Non-Hodgkinâ€™s Lymphoma: The Tei Index Evaluation. <i>Journal of Personalized Medicine</i> , 2022, 12, 290.	2.5	2
3	Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2022, 14, 1439.	3.7	6
4	Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2022, 14, 61.	3.7	5
5	Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi. <i>Tumori</i> , 2021, 107, 91-94.	1.1	11
6	18F-FDG PET/CT Cannot Substitute Endoscopy in the Staging of Gastrointestinal Involvement in Mantle Cell Lymphoma. A Retrospective Multi-Center Cohort Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 123.	2.5	3
7	A New Ensemble Method for Detecting Anomalies in Gene Expression Matrices. <i>Mathematics</i> , 2021, 9, 882.	2.2	12
8	The Impact of Healthy Lifestyles on Late Sequelae in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors. A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2021, 13, 3135.	3.7	9
9	Late Neurological and Cognitive Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2021, 13, 3401.	3.7	9
10	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta OncolÃ³gica</i> , 2021, 60, 1527-1533.	1.8	2
11	Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective realâ€™world study. <i>European Journal of Haematology</i> , 2020, 104, 581-587.	2.2	10
12	A Novel Deep Learning Approach in Haematology for Classification of Leucocytes. <i>Smart Innovation, Systems and Technologies</i> , 2019, , 265-274.	0.6	6
13	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicineâ€™Results from the Italian â€™Back to Lifeâ€™ project. <i>Quality of Life Research</i> , 2018, 27, 1545-1554.	3.1	9
14	Association between proteomic profile and molecular response in chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 1016-1018.	1.3	0
15	A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 608-613.	2.0	19
16	Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis. <i>Cell Reports</i> , 2017, 20, 1654-1666.	6.4	258
17	Improving Provision of Care for Long-term Survivors of Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e1-e9.	0.4	17
18	u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression. <i>BMC Cancer</i> , 2017, 17, 215.	2.6	20

#	ARTICLE	IF	CITATIONS
19	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 42-49.	0.8	31
20	Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. <i>Leukemia and Lymphoma</i> , 2017, 58, 552-559.	1.3	9
21	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016, 60, 154-165.	2.8	22
22	A novel approach to evaluate blood parameters using computer vision techniques. , 2016, , .		35
23	Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016, 18, 536-540.	5.3	24
24	Improvements in haematology for home health assistance and monitoring by a web based communication system. , 2016, , .		7
25	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016, 57, 2370-2374.	1.3	5
26	Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016, 40, 24-29.	0.8	6
27	Role of WB-MR/DWIBS compared to 18F-FDG PET/CT in the therapy response assessment of lymphoma. <i>Radiologia Medica</i> , 2016, 121, 132-143.	7.7	28
28	A supervised CAD to support telemedicine in hematology. , 2015, , .		12
29	The European Accreditation of Istituto Tumori Giovanni Paolo II of Bari. <i>Tumori</i> , 2015, 101, S14-S18.	1.1	0
30	A voluminous mass as an initial clinical symptom of multiple myeloma: A case report. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1689-1691.	1.8	1
31	Î±Î²-Double Negative CD4/CD8 (CD56) T cell (DNTs) in metastatic melanoma: basal frequency and behaviour during Ipilimumab treatment. Preliminary evaluations. <i>Journal of Translational Medicine</i> , 2015, 13, O10.	4.4	4
32	Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1623-1635.	3.4	58
33	Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP). <i>Leukemia Research</i> , 2015, 39, 1166-1171.	0.8	5
34	Azacitidine in the front-line treatment of therapy-related myeloid neoplasms: a multicenter case series. <i>Anticancer Research</i> , 2015, 35, 461-6.	1.1	6
35	Challenges and Opportunities of MicroRNAs in Lymphomas. <i>Molecules</i> , 2014, 19, 14723-14781.	3.8	26
36	HIF-1Î± of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 847-858.	7.0	54

#	ARTICLE	IF	CITATIONS
37	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. <i>Leukemia Research</i> , 2014, 38, 1446-1450.	0.8	13
38	FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. <i>BMC Cancer</i> , 2014, 14, 396.	2.6	10
39	Targeted Strategies in the Treatment of Primary Gastric Lymphomas: From Rituximab to Recent Insights into Potential New Drugs. <i>Current Medicinal Chemistry</i> , 2014, 21, 1005-1016.	2.4	4
40	Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma. <i>Hellenic Journal of Nuclear Medicine</i> , 2014, 17 Suppl 1, 40-9.	0.3	14
41	Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 473-475.	3.4	0
42	Efficacy and safety of bendamustine for the treatment of patients with recurring <sc>H</sc>odgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 160, 207-215.	2.5	57
43	Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. <i>Hematological Oncology</i> , 2013, 31, 179-182.	1.7	20
44	Changes in angiogenesis and hypoxia-inducible factor-1 protein expression in relapsed/refractory indolent non- <sc>H</sc>odgkin lymphomas. <i>British Journal of Haematology</i> , 2013, 163, 640-645.	2.5	11
45	Complete Response to Second Line Paclitaxel Every 2 Weeks of Eyelid Kaposi Sarcoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2013, 29, e114-e115.	0.8	2
46	Antineoplastic drug-induced bradyarrhythmias. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 739-751.	2.4	10
47	mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma. <i>Current Medicinal Chemistry</i> , 2012, 19, 945-954.	2.4	11
48	Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. <i>Oncogene</i> , 2012, 31, 2258-2269.	5.9	31
49	Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S111-S117.	3.4	13
50	Synchronous Presentation of B-Cell Chronic Lymphocytic Leukemia/Small-Cell Lymphoma and Colon Adenocarcinoma Within the Same Mesenteric Lymph Nodes and a Single Liver Metastasis. <i>Journal of Clinical Oncology</i> , 2011, 29, e11-e13.	1.6	8
51	Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 1935-1946.	7.0	75
52	Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. <i>European Journal of Cancer</i> , 2010, 46, 420-429.	2.8	65
53	Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 5369-5378.	7.0	91
54	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet</i> , The, 2009, 374, 1512-1520.	13.7	588

#	ARTICLE	IF	CITATIONS
55	Activity and Safety of Pegylated Liposomal Doxorubicin as First-Line Therapy in the Treatment of Non-Visceral Classic Kaposi's Sarcoma: A Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1578-1580.	0.7	57
56	Endothelial Differentiation of Hematopoietic Stem and Progenitor Cells from Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2008, 14, 1678-1685.	7.0	44
57	Primary intracranial dural B cell small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1437-1443.	1.3	11
58	Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). <i>Hematology</i> , 2007, 12, 141-147.	1.5	97
59	Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 37, 719-724.	2.4	96